Neurocrine Biosciences
NBIX
#1407
Rank
A$22.33 B
Marketcap
A$222.11
Share price
-1.41%
Change (1 day)
19.79%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$9.99

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$9.37. In 2025 the company made an earnings per share (EPS) of A$6.73 an increase over its 2024 EPS that were of A$4.72.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$9.9948.48%
2025A$6.7342.6%
2024A$4.7233.07%
2023A$3.5557.76%
2022A$2.2569.47%
2021A$1.33-78.21%
2020A$6.09990%
2019A$0.5681.82%
2018A$0.31-113.5%
2017A-$2.280.62%
2016A-$2.2657.28%
2015A-$1.4425.61%
2014A-$1.1518.84%
2013A-$0.96-1085.71%
2012A$0.09775

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.83-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.87-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$39.42 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.28-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.83-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$4.89-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$41.76-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.66-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK